134 related articles for article (PubMed ID: 12396726)
1. Cytotoxicity of combinations of IFN-beta and chemotherapeutic drugs.
Brickelmaier M; Carmillo A; Goelz S; Barsoum J; Qin XQ
J Interferon Cytokine Res; 2002 Aug; 22(8):873-80. PubMed ID: 12396726
[TBL] [Abstract][Full Text] [Related]
2. The synergistic cytotoxicity of cisplatin and taxol in killing oral squamous cell carcinoma.
Huang GC; Liu SY; Lin MH; Kuo YY; Liu YC
Jpn J Clin Oncol; 2004 Sep; 34(9):499-504. PubMed ID: 15466821
[TBL] [Abstract][Full Text] [Related]
3. Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma.
Yamamoto K; Mizutani Y; Nakanishi H; Fujiwara J; Ishida H; Toiyama D; Abe K; Hayashi I; Okada K; Kawauchi A; Mizuno M; Yoshida J; Miki T
Int J Oncol; 2008 Sep; 33(3):565-71. PubMed ID: 18695887
[TBL] [Abstract][Full Text] [Related]
4. Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo.
Kase S; Kubota T; Watanabe M; Furukawa T; Tanino H; Ishibiki K; Teramoto T; Kitajima M
Anticancer Res; 1993; 13(2):369-73. PubMed ID: 8517649
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative effects of interferons -alpha and -beta in combination with 5-fluorouracil, cisplatin, and cis- and trans-retinoic acid in three human lung carcinoma cell lines.
Arbaje YM; Bittner G; Yingling JM; Storer B; Schiller JH
J Interferon Res; 1993 Feb; 13(1):25-32. PubMed ID: 8384234
[TBL] [Abstract][Full Text] [Related]
6. Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer.
Blaauboer A; Booy S; van Koetsveld PM; Karels B; Dogan F; van Zwienen S; van Eijck CHJ; Hofland LJ
BMC Cancer; 2020 Sep; 20(1):913. PubMed ID: 32967656
[TBL] [Abstract][Full Text] [Related]
7. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
Bunn PA; Helfrich B; Soriano AF; Franklin WA; Varella-Garcia M; Hirsch FR; Baron A; Zeng C; Chan DC
Clin Cancer Res; 2001 Oct; 7(10):3239-50. PubMed ID: 11595720
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
van Moorsel CJ; Pinedo HM; Veerman G; Bergman AM; Kuiper CM; Vermorken JB; van der Vijgh WJ; Peters GJ
Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of 2',2'-difluorodeoxycytidine (gemcitabine) combined with interferon in human renal cell carcinoma cell lines.
Rohde D; Hayn HK; Blatter J; Jakse G
Int J Oncol; 1998 Jun; 12(6):1361-6. PubMed ID: 9592200
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy of the taxanes and antimetabolites: its use and limitations.
Smorenburg CH; Sparreboom A; Bontenbal M; Verweij J
Eur J Cancer; 2001 Dec; 37(18):2310-23. PubMed ID: 11720823
[TBL] [Abstract][Full Text] [Related]
11. Interferon receptors and the caspase cascade regulate the antitumor effects of interferons on human pancreatic cancer cell lines.
Saidi RF; Williams F; Ng J; Danquah G; Mittal VK; ReMine SG; Jacobs MJ
Am J Surg; 2006 Mar; 191(3):358-63. PubMed ID: 16490547
[TBL] [Abstract][Full Text] [Related]
12. In vitro synergism between 5-fluorouracil and natural beta interferon in human colon carcinoma cells.
Guglielmi A; Aschele C; Mori A; Baldo C; Russo P; Debernardis D; Valenti M; Bruno S; Taverna M; Rosso R
Clin Cancer Res; 1995 Nov; 1(11):1337-44. PubMed ID: 9815929
[TBL] [Abstract][Full Text] [Related]
13. Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines.
Edelman MJ; Quam H; Mullins B
Cancer Chemother Pharmacol; 2001 Aug; 48(2):141-4. PubMed ID: 11561780
[TBL] [Abstract][Full Text] [Related]
14. Colossolactone-G synergizes the anticancer properties of 5-fluorouracil and gemcitabine against colorectal cancer cells.
Algehani RA; Abou Khouzam R; Hegazy GA; Alamoudi AA; El-Halawany AM; El Dine RS; Ajabnoor GA; Al-Abbasi FA; Baghdadi MA; Elsayed I; Hattori M; Al-Abd AM
Biomed Pharmacother; 2021 Aug; 140():111730. PubMed ID: 34062410
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Loprevite M; Favoni RE; de Cupis A; Pirani P; Merlo F; Grossi F; Ardizzoni A
Int J Oncol; 1999 Oct; 15(4):787-92. PubMed ID: 10493963
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
Tonkinson JL; Worzalla JF; Teng CH; Mendelsohn LG
Cancer Res; 1999 Aug; 59(15):3671-6. PubMed ID: 10446980
[TBL] [Abstract][Full Text] [Related]
17. Interferon-beta is more potent than interferon-alpha in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs.
Damdinsuren B; Nagano H; Sakon M; Kondo M; Yamamoto T; Umeshita K; Dono K; Nakamori S; Monden M
Ann Surg Oncol; 2003 Dec; 10(10):1184-90. PubMed ID: 14654475
[TBL] [Abstract][Full Text] [Related]
18. Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma.
Mynhardt C; Damelin LH; Jivan R; Peres J; Prince S; Veale RB; Mavri-Damelin D
J Cell Biochem; 2018 Jan; 119(1):1193-1203. PubMed ID: 28722177
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.
O'Reilly T; McSheehy PM; Wartmann M; Lassota P; Brandt R; Lane HA
Anticancer Drugs; 2011 Jan; 22(1):58-78. PubMed ID: 20890178
[TBL] [Abstract][Full Text] [Related]
20. Diltiazem potentiates the cytotoxicity of gemcitabine and 5-fluorouracil in PANC-1 human pancreatic cancer cells through inhibition of P-glycoprotein.
El-Mahdy HA; El-Husseiny AA; Kandil YI; Gamal El-Din AM
Life Sci; 2020 Dec; 262():118518. PubMed ID: 33011221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
